Investorideas.com newswire, breaking biotechnology and pharma news

Friday, January 31, 2020

New #Stocks added to Investor Ideas Stock Directories (NASDAQ: $IMAB) (NASDAQ: $PDCO) (NASDAQ: $LIZI) (NYSE: $DNK) (TSXV: $OCG.V) (TSXV: $HPQ.V)

New #Stocks added to Investor Ideas Stock Directories (NASDAQ: $IMAB) (NASDAQ: $PDCO) (NASDAQ: $LIZI) (NYSE: $DNK) (TSXV: $OCG.V) (TSXV: $HPQ.V)  

Biotech, Pets, Tech, Real Estate, Mining and Cleantech Sectors




Point Roberts WA, Delta BC, January 31, 2020 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces its weekly roundup of stocks added to its global stock directories in biotech, pets, tech, real estate, mining and cleantech.


The newest biotech companies are involved in producing pharmaceuticals and biologics and in providing diagnostic technologies, genetic analyzing and protective apparel.

The latest pet companies are involved in animal health products and services, while the newest tech companies are involved in wireless/software and internet content/mobile apps, respectively.

The newest real estate companies offer rental services and financing.

The latest cleantech company has partnered with tech companies to provide renewable energy products while the latest mining company has operations in Colombia.

New Biotech Companies:
I-MAB (NasdaqGS:IMAB) is a dynamic, global biotech company exclusively focused on developing biologics of novel or highly differentiated in the therapeutic areas of immuno-oncology and autoimmune diseases. I-Mab's mission is to bring transformational medicines to patients through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven preclinical and clinical development expertise, and world-class GMP manufacturing capabilities.

Lipidor AB (Nasdaq First North: LIPI) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

AstraZeneca plc (NYSE: AZN) discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.

Alpha Pro Tech, Ltd. (NYSE: APT) is the parent company of Alpha Pro Tech, Inc. and Alpha ProTech Engineered Products, Inc. Alpha Pro Tech, Inc. develops, manufactures and markets innovative disposable and limited-use protective apparel products for the industrial, clean room, medical and dental markets. Alpha ProTech Engineered Products, Inc. manufactures and markets a line of construction weatherization products, including building wrap and roof underlayment. The Company has manufacturing facilities in Salt Lake City, Utah; Nogales, Arizona; Valdosta, Georgia; and a joint venture in India.

Co-Diagnostics Inc (NASDAQ: CODX) a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

LexaGene Holdings, Inc. (OTCQB: LXXGFTSX-V: LXG) is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go'. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

New Pet Companies:
Patterson Companies, Inc. (NasdaqGS:PDCO) connects dental and animal health customers in North America and the U.K. to the latest products, technologies, services and innovative business solutions that enable operational and professional success. The 2001 acquisition of Webster Veterinary marked Patterson’s entry into the animal health industry, and the 2015 acquisition of Animal Health International, Inc., firmly positioned Patterson as the largest animal health product distributor in North America. In addition to serving retail and farm stores, our animal health businesses provide products, equipment, technology and solutions to private practice veterinary clinics, group- and corporate-owned veterinary clinics and hospitals, and livestock producers across the companion animal, production animal and equine markets. The increase in pet ownership and health care expenditures on those pets, along with the increasing global middle class demand for animal protein, are keys to growth in the markets we serve

Central Garden & Pet Company (NasdaqGS:CENT) is a leading innovator, producer and distributor of branded and private label products for the lawn & garden and pet supplies markets. Committed to new product innovation, our products are sold to specialty independent and mass retailers. Participating categories in Pet include: Animal health and the brands ADAMS™, COMFORT ZONE®, FARNAM®, HORSE HEALTH™ and VITAFLEX®; aquatics and reptile and the brands AQUEON®, CORALIFE®, SEGREST™ and ZILLA®; bird & small animal and the brands KAYTEE®, Forti-Diet® and CRITTER TRAIL®; and dog & cat and the brands TFH™, NYLABONE®, FOUR PAWS®, IMS®, CADET®, DMC™, K&H Pet Products™, PINNACLE® and AVODERM®. We also provide a host of other application-specific pet brands and supplies. Central Garden & Pet Company is based in Walnut Creek, California, and has approximately 5,800 employees, primarily in North America.

Phibro Animal Health Corporation (NasdaqGS:PAHC) is a diversified global developer, manufacturer and supplier of a broad range of animal health and mineral nutrition products for livestock, helping veterinarians and farmers produce healthy, affordable food while using fewer natural resources.

New Tech Companies:
Iota Communications, Inc. (OTC:IOTC) is a wireless network carrier and software applications provider dedicated to the Internet of Things. Iota sells recurring-revenue solutions that optimize energy usage, sustainability and operations for commercial and industrial facilities both directly and via third-party relationships. Iota also offers important ancillary products and services which facilitate the adoption of its subscription-based services, including solar energy, LED lighting, and HVAC implementation services.

LIZHI INC. (NasdaqGS:LIZI) is a leading online UGC audio community and interactive audio entertainment platform in China, with a mission to enable everyone to showcase vocal talent. The Company is aiming to bring people closer together through voices. Since launching Lizhi app in 2013, LIZHI has cultivated a vibrant and growing community encouraging audio content creation and sharing.  Now LIZHI is an audio wonderland offering a wide range of podcasts and audio entertainment products and features, including audio live streaming and various interactive audio products, empowering users to enjoy an immersive and diversified entertainment experience through audio.
LIZHI envisions a global audio community – a place where everyone can create, share and connect with each other through voices and across cultures.      

New Real Estate Companies:
PHOENIX TREE HOLDINGS LTD (NYSE:DNK) one of the largest co-living platforms in China with the fastest growth, is redefining the residential rental market through technology and aims to help people live better. Empowered by data, technology, and a large-scale apartment network, Danke's vibrant and expanding ecosystem connects and benefits property owners, residents and third-party service providers, and delivers quality and best-in-class services through an innovative "new rental" business model featuring centralization, standardization, and a seamless online experience.

VELOCITY FINANCIAL, LLC (NYSE:VEL) Based in Westlake Village, California, Velocity is a vertically integrated real estate finance company that primarily originates and manages investor loans secured by 1-4 unit residential rental and small commercial properties. Velocity originates loans nationwide across an extensive network of independent mortgage brokers it has built and refined over 15 years.

New Mining Companies:
Outcrop Gold Corp. (TSXV: OCG) s a gold prospect generator active in Colombia acquiring gold exploration projects with world-class discovery potential. Outcrop performs its own grassroots exploration and then employs a joint venture business model on its projects to maximize investor exposure to discovery and minimize financial risk.

New Cleantech Companies:
HPQ Silicon Resources Inc.  (TSXV: HPQ.V; FWB: UGE; OTC: URAGF) is developing, with PyroGenesis Canada Inc. (PYR.V), a high-tech company that designs, develops, manufactures and commercializes plasma base processes, the innovative PUREVAPTM “Quartz Reduction Reactors” (QRR), a truly 2.0 Carbothermic process (patent pending), which will permit the One Step transformation of Quartz (SiO2) into High Purity Silicon (Si) at prices that will propagate its considerable renewable energy potential.  The Gen3 PUREVAPTM QRR pilot plant that will validate the commercial potential of the process is scheduled to start during Q1 2020. HPQ, working with PyroGenesis, is also developing a process that can take the High Purity Silicon (Si) made by the PUREVAPTM and manufacture Spherical Silicon Metal nano-powders for Next Gen Li-ion batteries.  During Q1 2020, the plan is to validate our game changing manufacturing approach using a modified Gen2 PUREVAPTM reactor to produce spherical Silicon Metal (Si) nano-powders samples for industry participants and research institutions’.
Concurrently, HPQ is also working with industry leader Apollon Solar to develop a manufacturing capability that uses the High Purity Silicon (Si) made with the PUREVAP™ to make Porous silicon wafers needed for solid-state Li-ion batteries.  The first Silicon wafer should be ready to be ship for testing to a battery manufacture (under NDA) during Q1 2020. Finally, with Apollon Solar, we are also looking into developing a metallurgical pathway of producing Solar Grade Silicon Metal (SoG Si) that will take full advantage of the PUREVAPTM QRR one-step production of Silicon (Si) material of 4N+ purity with low boron count (< 1 ppm). All in all, HPQ focus is becoming the lowest cost producer of Silicon Metal (Si), High Purity Silicon Metal (Si), Spherical Si nano-powders for Next Gen Li-ion batteries, Porous Silicon Wafers for Solid states Li-ion batteries, Porous Silicon Powders for Li-ion batteries and Solar Grade Silicon Metal (SoG-Si).

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.
We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.      

Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto CornerPlay by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate ChangeExploring Mining and the AI Eye.

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas
Download our Mobile App for iPhone and Android  

Sign up to get Investorideas.com original branded content - podcasts and commentary in the hottest sectors

To sponsor a daily podcast for the month or to be an expert guest please contact us!

Contact Investorideas.com
800-665-0411










#Cannabis/ Therapeutic #Stock News-American Premium Water Corp (OTC: $HIPH) Expanded Vanexxe #VaricoseVein Treatment Product Distribution in Australia with Nutra Pty. Ltd

#Cannabis/ Therapeutic #Stock News-American Premium Water Corp (OTC: $HIPH) Expanded Vanexxe #VaricoseVein Treatment Product Distribution in Australia with Nutra Pty. Ltd

The global varicose vein treatment market was valued at $376.64 million in 2017, and is expected to reach $589.06 million by 2025, growing at a CAGR of 5.7% from 2018 to 2025.- Allied Market Research


PLAYA VISTA, CA, January 31, 2020 (Investorideas.com Newswire) American Premium Water Corporation (OTC: HIPH) recently reported that Canyon Create Corp, the manufacturer of Vanexxe has entered into a Letter of Intent (LOI) with Nutra Pty. Ltd. (Nutra), an Australian corporation with extensive reach in distribution of personal products, to engage in the licensed production and sale of Vanexxe throughout Australia and Southeast Asia. The Company has an equitable interest in Canyon Create Corp.

American Premium Water Corporation CEO Ryan Fishoff commented, “This is an exciting day for Vanexxe! Not only is this ground breaking product expanding to Australia, its also being evaluated by the TGA to be classified for therapeutic use. If approval is given, it will greatly expand the number of channels that can sell the product. It will also offer further validation of the product and its efficacy. The LOI with Nutra Pty falls in line with our focus on international expansion, and has been in the works for some time, as the Company stated back in July that it was in discussions with distributors across the Pacific Rim. Establishing a foothold in the Pacific has been a stated goal of the Company’s. As we move into 2020, we will continue to focus on expanding into this region. I look forward to updating shareholders when the Nutra Pty LOI is completed and the Company’s other activities in the area.”

The Therapeutic Goods Administration (TGA) is the regulatory body for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in Australia. The LOI with Nutra stipulates that they would be responsible for the manufacturing and distribution of Vanexxe in Australia and surrounding regions in Southeast Asia. Nutra will also take the lead in shepherding the product through the approval process of the TGA. Australia is one of the world’s largest economies, having the 14th largest GDP globally.

Canyon Create Founder and President, Campbell McAuley, said: “This is the most encouraging news to date that we will be able to have our products marketed extensively in Australia and in the Southeast Asian region based on this anticipated approval by the TGA. We are confident that Nutra is an excellent manufacturing partner that will be able to meet our expectations, resulting in what we project will be the production and sale of hundreds of thousands of units of Vanexxe, as well as our other skin care topical brands.”  

LALPINA CBD water can be purchased online at visiting https://www.singleseed.com/product/lalpina-cbd-water-6-pack/

LYNKS Pet CBD Water can be purchased online:

Vanexxe can be purchased on Amazon here

Vanexxe Varicose Vein Treatment - vein support for varicose veins and to help reduce the appearance of varicose veins



Price: $49.99 ($25.00 / Fl Oz)
·        VISIBLE RESULTS IN 45 minutes - 2 hours THANKS TO THESE ALL NATURAL INGREDIENTS Ginko Biloba, Activated B Vitamins, Antioxidants, and Peptides
·        We pride ourselves on lab-tested, pesticide, metal, toxin, and cruelty free products. All of our product ingredients are ethically formulated in FDA approved laboratories and CGMP compliant facilities. We insure performance-based ethical products with the collaboration of industry leading dermatologists, clinicians, aroma therapists, skincare specialists and beauty experts.

The Company’s research report was recently updated by Ludlow Research with a short-term price target of $0.03. To read full report, risks, and disclosures, click here

About American Premium Water Corp.
American Premium Water (HIPH) is a diversified luxury consumer products company focused on businesses in the health and beauty and biotech sectors. The company is focused on harnessing the powers of Nano technologies paired without cannabidiol (CBD) to treat health disorders and enhance quality of life. The company’s portfolio includes the LALPINA Hydro and LALPINA CBD brands (www.lalpinahydrocbd.com),  Gents (www.gentsco.com), Vanexxe (www.vanexxe.com) and plant + body essentials (www.plantbodyessentials.com).

American Premium Water strives in providing only the highest quality CBD sources for its products, with quality control being one of our first and foremost focuses. The Company aims for this standard not only for compliance reasons, but also to provide our customers the highest quality product possible.

About Canyon Create Corp.
Canyon Create Corp., a Nevada Corporation, is the developer of Vanexxe (www.vanexxe.com), a patented cosmetic cream that uses a proprietary formulation to eliminate the appearance of varicose veins. The product works by simultaneously bringing  heightened blood flow to the bulged vein valve, allowing it to pull away from the dermis and return to a more normal condition, and increases the elasticity in the upper skin layers to provide healthier skin, assisting in moving the vein back to a non-visible location. 

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). American Premium Water Corporation cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. American Premium Water Corporation undertakes no obligation to revise these statements following the date of this news release.  Additional details of the Company's business can be found in its public disclosures as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

This press release is issued on behalf of the Board of Directors of American Premium Water Corporation.

Investor Relations
888-983-0054

The global varicose vein treatment market was valued at $376.64 million in 2017, and is expected to reach $589.06 million by 2025, growing at a CAGR of 5.7% from 2018 to 2025.- Allied Market Research

News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release HIPH is a paid for news release on Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com

Sign up for free stock news alerts at Investorideas.com



Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories








Get more Biotech Investor Ideas – news, articles and stock directories 




Tuesday, January 28, 2020

#BioPharma #Stocks Making the Headlines fighting #Coronavirus and #Bacteria - (NASDAQ: $CTXR) (NASDAQ: $INO) (NASDAQ: $NVAX), (NYSE: $NNVC) (NASDAQ: $MRNA)


#BioPharma #Stocks Making the Headlines fighting #Coronavirus and #Bacteria - (NASDAQ: $CTXR) (NASDAQ: $INO) (NASDAQ: $NVAX), (NYSE: $NNVC) (NASDAQ: $MRNA)

Point Roberts WA, Delta BC – January 28, 2020 - Investorideas.com, a leading investor news resource covering pharmaceutical and biotechnology stocks releases a special report on the opportunity within the specialty drug segment of the sector to address viral outbreaks and bacterial resistance, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR).

Certain social and technological advancements as well as new and deadlier viral (coronavirus) and bacterial outbreaks are forcing innovative business approaches for this competitive sub-sector and specialty companies are answering the call!


Looking at the current headline attention of the coronavirus, Infectioncontroltoday.com also addressed the current crisis of antimicrobial resistance. “Now that the planet’s attention is turned toward infectious disease thanks to the spotting of coronavirus in the United States, the World Health Organization (WHO) took the opportunity to point to another problem: the growing shortage of antibiotics available to fight all pathogens.”

A WHO press release reported, ”Tedros Adhanom Ghebreyesus, PhD, the director-general of WHO, said in the press release that “never has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent. Numerous initiatives are underway to reduce resistance, but we also need countries and the pharmaceutical industry to step up and contribute with sustainable funding and innovative new medicines.”

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products is in the midst of bringing their products to market having recently announced a positive outcome of the pre-specified interim futility analysis for the Phase 3 clinical trial of Mino-Lok® vs. standard-of-care antibiotic locks.
The analysis was conducted by the Mino-Lok trial Data Monitoring Committee ("DMC"), an independent panel of experts charged with periodically monitoring the safety and efficacy of the progress of the pivotal trial. The Company reached and completed the pre-specified 40% enrollment required for the interim futility analysis in late September and, based on the analysis of the data and recommendations of the DMC, will proceed with the current trial as planned. Topline data from the superior efficacy interim analysis, the next major milestone in the Mino-Lok trial, is expected in the first half of 2020.  The market potential for an effective antibiotic lock therapy is estimated at $750 million per year in the US and approximately $1.5 billion per year worldwide.

"We are extremely happy and proud that the first independent expert review of the patient data in our Mino-Lok trial concludes that our study is on track. Enrollment has continued since finalizing the 40% level futility report, and we have now reached the midpoint of our study. The DMC will evaluate clinical data at the 75% level of enrollment to see if Mino-Lok demonstrates superior efficacy versus standard-of-care antibiotic locks," said Myron Holubiak, Chief Executive Officer of Citius. "We would also like to thank all of the patients, study investigators, and support personnel at the 32 clinical sites that are participating in our trial. Lastly, we also want to acknowledge the research and guidance of Dr. Issam Raad and his team at MD Anderson Cancer Center in advancing this novel therapy."

Citius Pharmaceuticals, Inc. “Saving Lives of Hospital Patients with Catheters Infected by Deadly Bacteria” :

Citius was recently featured in a recent  edition of BiotechStock Review, which discussed the Citius “Mino-Lok” treatment - “created to kill infected catheters, Mino-Lok was developed clinicians and technologists at the M.D. Anderson Cancer Center. The Mini-Lok technology while complex is easy for investors to understand. Their market is huge, estimated at $500 million to $1 billion annually and fairly-easy for investors to identify. The need for Mino-Lok is rather obvious as we will later explain. Also, studies to date have proven it to be much safer, more effective and less expensive than the alternatives and once again, easy for investors to grasp. Finally, the time (they’re in Phase III), path and cost to approval are modest in comparison to biotech companies creating drugs from scratch. A ‘five-fecta’ so to speak.”

Continued: “Part of the Citius business strategy is to build a successful company by developing and commercializing cost-effective products that address unmet medical needs. It seeks to leverage the FDA’s 505(b)(2) pathway for new drug approvals and bring products to market faster and with lower cost than other FDA new drug approval pathways (meaning creating drugs from scratch).“

Continued “The Mino-Lok solution was created to kill bacteria that cannot be eradicated using current methods, resulting in the catheter needing to be removed and replaced. A dangerous and complicated procedure, Mino-Lok is the first – and only – therapy under investigation that can be used to sterilize and save the infected catheter.”

Continued “Mino-Lok is a patented solution that combines Minocycline, an antibiotic from the Tetracycline family with two other well-known ingredients. Minocycline was patented around the time we were born, as in 60 years ago – and prescribed 2 million times last year. It’s now a generic costing about $12 a dose. The list of use includes things like Anthrax and even the Bubonic Plague. So were guessing the FDA will recognize both its usefulness and safety profile.”

Fusionscienceacademy.com reports, “According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.”

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has seen opportunity in a viral disaster, having recently announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV). This initial CEPI funding will support Inovio's preclinical and clinical development through Phase 1 human testing of INO-4800, its new coronavirus vaccine matched to the outbreak strain. CEPI previously awarded Inovio a grant of up to $56 million for the development of vaccines against Lassa fever and Middle East Respiratory Syndrome (MERS), also caused by a coronavirus.

Inovio's participation in this developing effort is based on the ideal suitability of its DNA medicine platform to rapidly develop a vaccine against an emerging virus with pandemic potential, proven vaccine development capabilities and a strong track record of rapidly generating promising countermeasures against previous pandemic threats. Inovio was the first to advance its vaccine (INO-4700) against MERS-CoV, a related coronavirus, into evaluation in humans. Inovio is currently preparing to initiate a Phase 2 vaccine trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred.

In a recently published paper in Lancet Infectious Diseases, Inovio's Phase 1 study of its MERS-CoV vaccine demonstrated it was well tolerated and furthermore induced high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing.

Richard Hatchett, CEPI's CEO said, "Given the rapid global spread of the 2019-nCoV virus the world needs to act quickly and in unity to tackle this disease. Our intention with this work is to leverage our work with Inovio on the MERS coronavirus and rapid response platform to speed up vaccine development."

Dr. J. Joseph Kim, Inovio's President and CEO said, "We're extremely honored to expand our partnership with CEPI to tackle this new threat to global public health. Our DNA medicine platform represents the best modern day approach to combatting emerging pandemics. We have already demonstrated positive clinical outcomes with our vaccine against MERS-CoV, another coronavirus. Importantly, following the Zika viral infection outbreak, Inovio and our partners developed a vaccine that went from bench to human testing in just seven months – the fastest vaccine development on record in recent decades. We believe we can further improve upon this accelerated timeline to meet the current challenge of the emerging coronavirus 2019-nCoV."

Talking about stocks moving on potential vaccines for the Coronavirus, Zacks Research reported “Obviously, shares of vaccine manufacturers have gained sharply on concerns over the new virus. Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company, saw its shares soar 72% on Jan 21. The company is primarily manufacturing two late-stage vaccines for the flu and various other infectious diseases. Another nano-biopharmaceutical company, NanoViricides, Inc. NNVC (NYSE: NNVC) witnessed its shares climb more than 100%. After all, the company is known for developing nano-medicines for viral diseases like swine and bird influenza.”

Another specialty biotech company, Moderna, Inc. (NASDAQ: MRNA) is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Moderna just announced a new collaboration to develop an mRNA vaccine against the novel coronavirus (2019-nCoV).

From the news: Under the terms of the agreement, Moderna will manufacture an mRNA vaccine against 2019-nCoV, which will be funded by CEPI. The Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, collaborated with Moderna to design the vaccine. NIAID will conduct IND-enabling studies and a Phase 1 clinical study in the US.

From the news: Over the past four years Moderna has had six positive Phase 1 clinical readouts in its prophylactic vaccines modality and moved two additional programs into development. Moderna’s technology platform, fully integrated manufacturing site and development experience, combined with a multi-year relationship with the NIH, including exploring ways to respond to public health threats, allows for the rapid identification and advancement of a vaccine candidate against 2019-nCoV.

With antibiotic-resistant bacteria on the rise and new strains of viruses surfacing, opportunity abounds for the smaller specialty drug maker that can provide solutions.

Learn more about biotech stocks at Investorideas.com https://www.investorideas.com/BIS/
 
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news article featuring CTXR is a paid for news release on Investorideas.com – third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com
800-665-0411





 Get more Biotech Investor Ideas – news, articles and stock directories